Humacyte appoints Rick McElheny as senior VP of business development

Humacyte Inc. (NASDAQ: HUMA) announced the appointment of Rick McElheny as Senior Vice President of Business Development. McElheny will work with the company's leadership team to expand corporate collaborations for the development and commercialization of Humacyte's regenerative medicine pipeline.

McElheny brings more than 15 years of experience in corporate development and alliance management at biopharma companies. He previously served as Senior Vice President of Corporate Development and Alliance Management at Clearside Biomedical Inc. and was Founder and Vice President of Corporate Development at Vidara Therapeutics.

During his career, McElheny has led licensing and merger and acquisition transactions, including the $660 million sale of Vidara Therapeutics and over $250 million in out-licensing transactions at Clearside Biomedical. He holds an MBA from NYU Stern School of Business.

"We are delighted to welcome Rick to our team at such an exciting and transformative moment for the Humacyte," said Laura Nilason, Founder and Chief Executive Officer, according to the company's press release.

McElheny stated that he looks forward to working with the team to drive strategic partnerships for the company's pipeline, which includes Symvess and programs in coronary bypass graft surgery and the BioVascular Pancreas for Type 1 diabetes.

Humacyte is a commercial-stage biotechnology platform company that develops bioengineered human tissues. The company's Biologics License Application for its acellular tissue engineered vessel in the vascular trauma indication received FDA approval in December 2024.

You May Also Be Interested In

• Humacyte Phase 3 trial shows ATEV outperforms fistula in women
• Alnylam reports Phase 1b data for Huntington's drug brezosiran
• LKQ names Salvatore Abbate as CEO, effective December 15